<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617183</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P47 1.3</org_study_id>
    <nct_id>NCT05617183</nct_id>
  </id_info>
  <brief_title>Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Open-label, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to compare the Pharmacokinetics and Safety of the Auto-injector and&#xD;
      Pre-filled syringe of CT-P47 in Healthy Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CT-P47, containing the active ingredient tocilizumab, is a recombinant humanized monoclonal&#xD;
      antibody that is being developed as a similar biological medicinal product to&#xD;
      RoActemra/Actemra. The purpose of this study is to demonstrate the pharmacokinetics and&#xD;
      safety of the Auto-injector and Pre-filled syringe of CT-P47 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK similarity demonstration by AUC</measure>
    <time_frame>Day 43</time_frame>
    <description>Demonstrate PK similarity in terms of area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf) of CT-P47 SC administration via AI versus PFS in healthy subjects up to Day 43. The similarity of PK between CT-P47 AI vs CT-P47 PFS will be concluded if the 90% Cls for the ratios of geometric means of the comparison are entirely contained within the equivalence margin of 80% to 125% for AUC0-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK similarity demonstration by Cmax</measure>
    <time_frame>Day 43</time_frame>
    <description>Demonstrate PK similarity in terms of maximum serum concentration (Cmax) of CT-P47 SC administration via AI versus PFS in healthy subjects up to Day 43. The similarity of PK between CT-P47 AI vs CT-P47 PFS will be concluded if the 90% Cls for the ratios of geometric means of the comparison are entirely contained within the equivalence margin of 80% to 125% for Cmax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional PK evaluation</measure>
    <time_frame>Day 43</time_frame>
    <description>Evaluate additional PK in terms of AUC from time zero to the last quantifiable concentration (AUC0-last).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation by TEAEs</measure>
    <time_frame>Day 43</time_frame>
    <description>Evaluate safety in terms of treatment-emergent adverse events (TEAEs) of CT-P47.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>CT-P47 Auto-injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-P47 Pre-filled Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P47</intervention_name>
    <description>CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)</description>
    <arm_group_label>CT-P47 Auto-injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P47</intervention_name>
    <description>CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)</description>
    <arm_group_label>CT-P47 Pre-filled Syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subjects between the ages of 19 to 55 years, both inclusive.&#xD;
&#xD;
          2. Subject with a body weight of ≥60 and ≤100 kg for male and ≥50 and ≤100 kg for female&#xD;
             and a BMI between 18.5 and 28.0 kg/m2 (both inclusive) when rounded to the nearest&#xD;
             tenth.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A medical history and/or condition that is considered significant&#xD;
&#xD;
          2. Clinically significant allergic reactions, hypersensitivity&#xD;
&#xD;
          3. History or current infection of hepatitis B virus, hepatitis C virus, human&#xD;
             immunodeficiency virus, or syphilis&#xD;
&#xD;
          4. Active or latent Tuberculosis&#xD;
&#xD;
          5. History of malignancy&#xD;
&#xD;
          6. Previous exposure to tocilizumab or any drug that targets IL-6&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KyungSang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MinAh Chun</last_name>
    <phone>+82 32 850 5761</phone>
    <email>minah.chun@celltrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EnDa Ko</last_name>
    <phone>+82 32 850 5757</phone>
    <email>enda.ko@celltrion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyungSang Yu</last_name>
      <phone>81-2-2072-1666</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>October 25, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>March 24, 2023</last_update_submitted>
  <last_update_submitted_qc>March 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

